OVM-200

OVM-200 is an ROP vaccine targeting survivin
Clinical phase 1 - excellent initial results – solid tumours

OVM-200

OVM-200 is an ROP vaccine targeting survivin. Survivin is an ‘inhibitor of apoptosis’ protein that helps tumour cells evade attack by the body’s immune system.

Inactivating survivin leaves the tumour cells open to attack. Survivin is over expressed on the cell surface of over 90% of solid tumours.
Structure of Survivin

Structure of survivin

Overexpression of survivin in solid tumours

Overexpression of survivin in solid tumours

Structure of survivin

OVM-200: Phase 1 Clinical Trial

OVM-200 is in Phase 1 clinical development in the UK, at leading trial centres including The Christie in Manchester, Sarah Cannon Research Institute in London, University College hospital in London and The Churchill hospital in Oxford. See the ITV News article about the clinical trial here.

OVM-200 is being used to treat patients with advanced NSCLC (non small cell lung cancer), ovarian cancer and prostate cancer.

NHS The Christie logo
Oxford University Hospitals logo
HCA Healthcare logo
OVM UK, clinical trials - map

The Phase 1 trial of OVM-200 is the first time an ROP vaccine has been trialled in people and is aiming to show both safety and an immune response from the body’s immune system. The trial is in two parts:

Phase 1a is completed with 12 patients treated and the dose of OVM-200 chosen.

Phase 1b is ongoing with extended dosing up to 6 months in duration, in a further 24 patients.

Initial results are very positive, full results are expected towards the end of 2025.

OVM-200 Phase 1 Trial Design

ITV News film clip & article: Mum-of-two first to trial new cancer vaccine (Sept 2022)

en_GBEnglish